Advanced searches left 3/3

Carbon-14 - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 August 2022

* If you want to update the article please login/register

Absorption, Metabolism and Excretion of [14C]Chiauranib in Patients With Small Cell Lung Cancer

Chiauranib's particulars revealed high selectivity in the kinase inhibition profile but no activity was found on off-target non-target non-receptor kinases, proteins, GPCR, and ion channels, indicating a more effective drug safety profile in terms of clinical relevance. This trial is a material balance investigation of [14C]Chiauranib in patients with small cell lung cancer with the intention of learning more about the drug's absorption, metabolism, and excretion in the human body, as well as monitoring the subjects' health after treatment.

Source link: https://clinicaltrials.gov/ct2/show/NCT05371899


An Open-Label Mass Balance Study to Investigate the Pharmacokinetics, Excretion, and Recovery of Single-Dose Oral [14C]-Rodatristat Ethyl in Healthy Male Subjects

This is an open-label research to determine the PK and excretion of a single oral dose of [14C]-rodatristat ethyl. Around 6 healthy male patients will be admitted to the hospital and the following morning, a single oral suspension of rodatristat ethyl 600 mg containing a mixture of [12C]-rodathie ethyl and [14C]-rodatristat ethyl 600 microcuries of radioactivity will be sent to approximately 600 microcuries of radioactivity. Following dosing, serial whole blood and plasma PK testing, urine and feces samples will be collected until release. Subjects will remain in the clinic until at least Day 7. On two days in which a fecal sample is collected, a subject will be disqualified if complete recovery of the administered radioactive dose is u226590%, and the overall return of radioactive dose is u22641%. Total radioactivity, rodatristat ethyl, rodatristat, rodacristat, and metabolite will be determined in blood and fecal samples and metabolite.

Source link: https://clinicaltrials.gov/ct2/show/NCT05006118


A Phase I Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) in Healthy Male Subjects

Breast, lung, prostate, and bowel cancer are among the most common forms of cancer in the United Kingdom. 'Radiolabelled' means that the test medicine has a radioactive component that helps us to determine where the test medicine is in the body. In Part 1, volunteers will be given a single dose of 2 non-radiolabelled oral tablets in the fasted state followed by an intravenous injection of radiolabelled test medicine 1 hour 15 mins later. In Part 2, volunteers will be given a single oral dose of a radiolabelled oral tablet in the fasted state. Volunteers will be discharged on Day 8, but residents may be required to remain at the medical unit until Day 10, if the mass balance conditions are not met by Day 8. Volunteers will be sent a follow-up phone call between Day 15 and Day 19.

Source link: https://clinicaltrials.gov/ct2/show/NCT05419401

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions